{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:41:06Z","timestamp":1783996866162,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA247932"],"award-info":[{"award-number":["R01CA247932"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.cct.2021.106517","type":"journal-article","created":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T01:21:45Z","timestamp":1627176105000},"page":"106517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols"],"prefix":"10.1016","volume":"108","author":[{"given":"Nolan A.","family":"Wages","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany Jablonski","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Conaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina R.","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2021.106517_bb0005","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2014.59.8466","article-title":"Scientific review of phase I protocols with novel dose-escalation designs: how much information is needed?","volume":"33","author":"Iasonos","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2021.106517_bb0010","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-18-0203","article-title":"The impact of early-phase trial design in the drug development process","volume":"25","author":"Conaway","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cct.2021.106517_bb0015","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/10543406.2017.1289952","article-title":"Dose-finding designs for trials of molecularly targeted agents and immunotherapies","volume":"27","author":"Chiuzan","year":"2017","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.cct.2021.106517_bb0020","series-title":"Clinical Trials: A Methodologic Perspective","author":"Piantadosi","year":"2005"},{"key":"10.1016\/j.cct.2021.106517_bb0025","series-title":"Oncology Clinical Trials","author":"Kelly","year":"2010"},{"key":"10.1016\/j.cct.2021.106517_bb0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/107327481402100304","article-title":"Phase 1 trial design: is 3 + 3 the best?","volume":"21","author":"Hansen","year":"2014","journal-title":"Cancer Control"},{"key":"10.1016\/j.cct.2021.106517_bb0035","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cct.2021.106517_bb0040","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-09-1961","article-title":"Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee","volume":"16","author":"Ivy","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cct.2021.106517_bb0045","series-title":"Statistical methods for dose-finding experiments","first-page":"91","article-title":"Accelerated titration designs","author":"Dancey","year":"2006"},{"key":"10.1016\/j.cct.2021.106517_bb0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.conctc.2016.11.006","article-title":"Systematic comparison of the statistical operating characteristics of various phase I oncology designs","volume":"5","author":"Ananthakrishnan","year":"2017","journal-title":"Contemp Clin Trials Commun"},{"issue":"17","key":"10.1016\/j.cct.2021.106517_bb0055","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","article-title":"Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials","volume":"22","author":"Yuan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cct.2021.106517_bb0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase I clinical trials in cancer","volume":"46","author":"O\u2019Quigley","year":"1990","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2021.106517_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"issue":"8","key":"10.1016\/j.cct.2021.106517_bb0070","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/009286150103500416","article-title":"The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design","volume":"35","author":"Kang","year":"2001","journal-title":"Drug Inf J"},{"key":"10.1016\/j.cct.2021.106517_bb0075","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/009286150203600415","article-title":"An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials","volume":"36","author":"Kang","year":"2002","journal-title":"Drug Inf J"},{"key":"10.1016\/j.cct.2021.106517_bb0080","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/sim.2334","article-title":"A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials","volume":"25","author":"He","year":"2006","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2021.106517_bb0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cct.2008.10.006","article-title":"Range and trend of expected toxicity level (ETL) in standard a + B designs: a report from the Children\u2019s oncology group","volume":"30","author":"Chen","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.cct.2021.106517_bb0090","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1541-0420.2005.00311.x","article-title":"Continuous toxicity monitoring in phase II trials in oncology","volume":"61","author":"Ivanova","year":"2005","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2021.106517_bb0095","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cct.2021.106517_bb0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1740774508096474","article-title":"A comprehensive comparison of the continual reassessment method to the standard 3+3 dose escalation scheme in phase 1 dose-finding studies","volume":"5","author":"Iasonos","year":"2008","journal-title":"Clin Trials"},{"key":"10.1016\/j.cct.2021.106517_bb0105","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2013.54.6051","article-title":"Adaptive dose-finding studies: a review of model-guided phase I clinical trials","volume":"32","author":"Iasonos","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2021.106517_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0167-9473(98)00095-4","article-title":"Operating characteristics of the standard phase I clinical trial design","volume":"30","author":"Reiner","year":"1999","journal-title":"Comp Stat Data Analysis"},{"key":"10.1016\/j.cct.2021.106517_bb0115","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/annonc\/mdv266","article-title":"Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials","volume":"26","author":"Paoletti","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cct.2021.106517_bb0120","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1158\/1078-0432.CCR-15-2644","article-title":"Rendering the 3+3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy","volume":"22","author":"Nie","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cct.2021.106517_bb0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1200\/CCI.20.00122","article-title":"BOIN suite: a software platform to design and implement novel early-phase clinical trials","volume":"5","author":"Zhou","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.cct.2021.106517_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1740774519890146","article-title":"Designing and evaluating dose-escalation studies made easy: the MoDEsT web app","volume":"17","author":"Pallmann","year":"2020","journal-title":"Clin Trials"},{"key":"10.1016\/j.cct.2021.106517_bb0135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12885-018-4038-x","article-title":"A web tool for designing and conducting phase I trials using the continual reassessment method","volume":"18","author":"Wages","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cct.2021.106517_bb0140","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.1158\/1078-0432.CCR-17-0582","article-title":"Dose transition pathways: the missing link between complex dose-finding designs and simple decision-making","volume":"23","author":"Yap","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cct.2021.106517_bb0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1740774509105076","article-title":"Model calibration in the continual reassessment method","volume":"6","author":"Lee","year":"2009","journal-title":"Clin Trials"},{"key":"10.1016\/j.cct.2021.106517_bb0150","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/sim.4139","article-title":"Calibration of prior variance in the Bayesian continual reassessment method","volume":"30","author":"Lee","year":"2011","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2021.106517_bb0155","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/PO.21.00136","article-title":"Would the recommended dose have been different using novel dose-finding designs? Comparing dose-finding designs in published trials","volume":"5","author":"Silva","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cct.2021.106517_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cct.2017.04.006","article-title":"A Bayesian interval dose-finding design addressing Ockham\u2019s razor:mTPI-2","volume":"58","author":"Guo","year":"2017","journal-title":"Contemp Clin Trials."},{"key":"10.1016\/j.cct.2021.106517_bb0165","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/annonc\/mdx795","article-title":"Phase I\u2013II clinical trial design: a state-of-the-art paradigm for dose finding","volume":"29","author":"Yan","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cct.2021.106517_bb0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on p-values: context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am. Stat."},{"issue":"7","key":"10.1016\/j.cct.2021.106517_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159026","article-title":"AplusB: a web application for investigating A + B designs for phase I cancer clinical trials","volume":"11","author":"Wheeler","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cct.2021.106517_bb0180","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12874-017-0381-x","article-title":"Implementing the EffTox dose-finding design in the Matchpoint trial","volume":"17","author":"Brock","year":"2017","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.cct.2021.106517_bb0185","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/annonc\/mdw681","article-title":"Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies","volume":"28","author":"Wages","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cct.2021.106517_bb0190","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1158\/1078-0432.CCR-17-1069","article-title":"Implementation of a model-based design in a phase 1b study of combined targeted agents","volume":"23","author":"Wages","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cct.2021.106517_bb0195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/biostatistics\/3.1.51","article-title":"Non-parametric optimal design in dose finding studies","volume":"3","author":"O\u2019QuigleyJ","year":"2002","journal-title":"Biostatistics"},{"key":"10.1016\/j.cct.2021.106517_bb0200","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1002\/sim.2685","article-title":"Optimal designs for estimating the most successful dose","volume":"25","author":"O\u2019Quigley","year":"2006","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2021.106517_bb0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/biom.12158","article-title":"Simple benchmark for complex dose finding studies","volume":"70","author":"Cheung","year":"2014","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2021.106517_bb0210","article-title":"A benchmark for dose-finding studies with unknown ordering","author":"Mozgunov","year":"2021","journal-title":"Biostatistics"},{"key":"10.1016\/j.cct.2021.106517_bb0215","first-page":"189","article-title":"A benchmark for dose finding studies with continuous outcomes","volume":"21","author":"Mozgunov","year":"2020","journal-title":"Biostatistics"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421002536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421002536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:52:39Z","timestamp":1761555159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714421002536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":43,"alternative-id":["S1551714421002536"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2021.106517","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2021.106517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106517"}}